School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
School of Pharmacy, China Medical University, Taichung, Taiwan.
Int Ophthalmol. 2024 Oct 24;44(1):409. doi: 10.1007/s10792-024-03300-9.
INTRODUCTION: For ophthalmic patients, eye discomfort is a major problem that requires efficient pain treatment techniques. Pregabalin and gabapentin have surfaced as viable treatments for post-refractive surgery pain. To manage pain after refractive surgery, gabapentin and pregabalin were evaluated in this systematic review and meta-analysis. METHODOLOGY: A thorough search of databases including PubMed, Embase, Cochrane Library, and CINAHL was performed until March 2024. Inclusion criteria were randomized controlled trials assessing pregabalin and/or gabapentin's effectiveness in treating pain post-PRK, LASIK, and LASEK surgeries. RESULTS: Six studies met inclusion criteria, comprising a total of 391 patients undergoing various corneal surgeries. The meta-analysis revealed that pregabalin was significantly more effective than placebo in reducing pain on the first and second postoperative days (SMD day 1: -0.32, 95% CI -0.54, -0.09; SMD day 2: -0.55, 95% CI -0.85, -0.25), while gabapentin showed significant pain reduction on the second day only (SMD day 2: -0.42, 95% CI -0.71, -0.13). Combined analysis for both medications showed significant pain reduction on the first- and second-days post-surgery. No significant increase in adverse events was associated with either medication. Publication bias was minimal except for a slight asymmetry noted on day 1 effectiveness. CONCLUSION: Pregabalin and gabapentin are effective in reducing postoperative pain following refractive surgeries, with pregabalin showing a greater effect. Both medications are safe, with no significant increase in adverse events. Further research with standardized methodologies and long-term follow-up is recommended to optimize postoperative pain management in ocular surgeries.
引言:对于眼科患者来说,眼部不适是一个主要问题,需要有效的止痛治疗技术。普瑞巴林和加巴喷丁已成为屈光手术后疼痛的可行治疗方法。为了治疗屈光手术后的疼痛,本系统评价和荟萃分析评估了加巴喷丁和普瑞巴林。
方法:我们全面检索了包括 PubMed、Embase、Cochrane 图书馆和 CINAHL 在内的数据库,检索时间截至 2024 年 3 月。纳入标准为评估普瑞巴林和/或加巴喷丁治疗 PRK、LASIK 和 LASEK 手术后疼痛有效性的随机对照试验。
结果:符合纳入标准的共有 6 项研究,共纳入 391 例接受各种角膜手术的患者。荟萃分析显示,普瑞巴林在降低术后第 1 天和第 2 天疼痛方面明显优于安慰剂(SMD 第 1 天:-0.32,95%CI -0.54,-0.09;SMD 第 2 天:-0.55,95%CI -0.85,-0.25),而加巴喷丁仅在第 2 天显示出显著的疼痛减轻(SMD 第 2 天:-0.42,95%CI -0.71,-0.13)。两种药物联合分析显示术后第 1 天和第 2 天疼痛均有明显减轻。两种药物均未增加不良反应。除第 1 天疗效略有不对称外,发表偏倚较小。
结论:普瑞巴林和加巴喷丁可有效减轻屈光手术后的疼痛,普瑞巴林的效果更显著。两种药物均安全,不良反应无显著增加。建议采用标准化方法和长期随访进行进一步研究,以优化眼部手术的术后疼痛管理。
BMC Musculoskelet Disord. 2016-8-30
Cochrane Database Syst Rev. 2017-2-15
Rev Bras Anestesiol. 2017
Cochrane Database Syst Rev. 2020-12-18
J Ophthalmic Inflamm Infect. 2025-3-12
Rev Esp Anestesiol Reanim (Engl Ed). 2024-4
Medicine (Baltimore). 2023-2-10
J Taibah Univ Med Sci. 2022-8-15
Cureus. 2022-2-20
J Chin Med Assoc. 2022-2-1